Jun 08, 2021 / 12:50PM GMT
Ziyi Chen - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Thank you. Thank you, everyone, for joining this session at Goldman Sachs Global Healthcare Conference. This is Ziyi Chen, China heath care analyst at Goldman. So this session is for Zai Lab. So today, we are very pleased to have the Head of BD of Zai Lab, Jonathan Wang to join this session to discuss with us the most updated progress in BD and also the overall strategy of the Zai Lab. Thank you, Jonathan, for joining us.
Jonathan J. Wang - Zai Lab Limited - Executive VP & Head of Business Development
Thank you, Ziyi. And thank you, Goldman Sachs. Yes.
Questions and Answers:
Ziyi Chen - Goldman Sachs Group, Inc., Research Division - Equity AnalystYes. We're going to start with some of the broad questions. I think in the past 6 months, we have seen major progress in the BD side. I think -- thanks to you and your teams great effort on getting all those assets in the past 6 months, we have seen 4 major deals coming in and 4 major assets
Trustpilot
